TERAPIA REZŪM JAKO NOWOCZESNA METODA LECZENIA ŁAGODNEGO ROZROSTU PROSTATY
Keywords:
terapia Rezum, łagodny rozrost gruczołu krokowego, para wodna, małoinwazyjny zabieg chirurgicznySynopsis
Łagodny rozrost gruczołu krokowego (BPH) stanowi jedno z najczęstszych schorzeń urologicznych u mężczyzn w wieku powyżej 50 lat. Wraz z postępem technologicznym rozwijane są coraz mniej inwazyjne metody leczenia, które oferują porównywalną skuteczność do tradycyjnych technik chirurgicznych, przy jednoczesnym ograniczeniu ryzyka powikłań. Jedną z takich metod jest terapia parą wodną z użyciem systemu Rezūm. Terapia ta opiera się na dostarczaniu kontrolowanych impulsów pary wodnej bezpośrednio do tkanki rozrostowej, co prowadzi do jej selektywnej ablacji. Celem niniejszej pracy jest kompleksowe omówienie epidemiologii i patogenezy BPH, diagnostyki i klasycznych metod leczenia, a także dogłębna analiza terapii Rezūm – od historii jej rozwoju, przez mechanizm działania, po skuteczność, bezpieczeństwo i zastosowanie w praktyce klinicznej. Przedstawiono również przegląd aktualnych danych dotyczących efektywności tej metody, możliwych działań niepożądanych, kosztów oraz dostępności w Polsce. Praca może stanowić punkt wyjścia dla dalszych analiz porównawczych oraz wdrażania Rezūm do szerzej rozumianej praktyki klinicznej.
Chapters
-
TERAPIA REZŪM JAKO NOWOCZESNA METODA LECZENIA ŁAGODNEGO ROZROSTU PROSTATY
References
Rullis I, Shaeffer JA, Lilien OM. Incidence of prostatic carcinoma in the elderly. Urology. 1975;6(3):295-297.
Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8(3):439-443.
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474-479.
Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade?. Urology. 2000;56(5 Suppl 1):3-6.
Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002;59(2):245-250.
Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127(6):722-728.
Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3-S14.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bph
McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122-S128.
Emberton M, Fitzpatrick JM. The Reten World Study: a global epidemiological study of acute urinary retention. BJU Int. 2008;101(5):684-689.
Bosch JL, Bangma CH. Groeneveld FP, et al. The long-term relationship between a family history of LUTS and incident BPH. Eur Urol. 2008;54(3):693-700.
Hammarsten J, Högstedt B. Clinical, anthropometric, metabolic and insulin profile of men with prostate cancer and benign prostatic hyperplasia. J Urol. 2001;165(3):929-933.
Sarma AV, Jacobsen SJ, et al. Interrelationships among lower urinary tract symptoms, prostate volume, and PSA in black and white men: the Olmsted County Study. Urology. 2003;61(5):957-962.
Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008;167(8):925-934.
Maserejian NN, Giovannucci EL, McVary KT, et al. Dietary, lifestyle, and medical risk factors for benign prostatic hyperplasia. J Clin Epidemiol. 2011;64(3):247-255.
Roberts RO, Jacobsen SJ, Rhodes T, et al. Risk factors for benign prostatic hyperplasia in community-dwelling black and white men. J Urol. 2000;164(2):472-477.
Platz EA, Kawachi I, Rimm EB, et al. Race, ethnicity and benign prostatic hyperplasia in the health professionals follow-up study. J Urol. 2000;163(2):490-495.
Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005;40(3):121-128.
Andriole GL, Bruchovsky N, Chung LW, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of BPH. J Urol. 2004;172(4 Pt 1):1399-1403.
Izumi K, Mizokami A, Lin WJ, et al. Androgen receptor roles in the development of benign prostatic hyperplasia. Am J Pathol. 2013;182(6):1942-1949.
Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am. 1995;22(2):237-246.
Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202-1216.
Penna G, Mondaini N, Amuchastegui S, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin-8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome. Urology. 2007;69(4):735-740.
Nickel JC. Inflammation and benign prostatic hyperplasia. Urol Clin North Am. 2008;35(1):109-115.
Kyprianou N, Isaacs JT. Growth factors and their role in the development of benign prostatic hyperplasia. Prostate Suppl. 1990;3:61-69.
Chughtai B, Lee R, Te AE, et al. Role of inflammation in benign prostatic hyperplasia. Rev Urol. 2011;13(3):147-150.
Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007;9(4):181-190.
Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin, and combination therapy on lower urinary tract symptoms in men with BPH. N Engl J Med. 2010;362(13):1193-1203.
Tify I. Epidemiology, Symptoms of Benign Prostatic Hyperplasia and its Causes. Med Surg Urol. 2023;12:333. doi:10.35248/2168-9857.23.12.333.
Speakman MJ, Cheng X. Management of the complications of BPH/BOO. Indian J Urol. 2014;30(2):208-213. doi:10.4103/0970-1591.127856
Lu C, Wu HH, Lin T, et al. Is intravesical prostatic protrusion a risk factor for hydronephrosis and renal insufficiency in benign prostate hyperplasia patients?. Journal of the Chinese Medical Association. 2019;82(5):381-4.
Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the ICS. Neurourol Urodyn. 2002;21(2):167-178.
Doble A, Carter SS. Ultrasonography and clinical assessment in the evaluation of benign prostatic hypertrophy. Br J Urol. 1989;63(5):521-524.
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.
Bosch JL, Hop WC, Kirkels WJ, et al. The International Prostate Symptom Score in a community-based sample of men. J Urol. 1995;154(1):174-178.
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Engl J Med. 2003;349(25):2387-2398.
Roehrborn CG. 5-Alpha reductase inhibitors prevent disease progression in men with benign prostatic hyperplasia. Urology. 2001;58(6 Suppl 1):17-24.
Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int. 1999;83(3):227-237.
Strebel RT, Kaplan SA. The state of TURP through a historical lens. World J Urol. 2021;39(7):2255-2262. doi:10.1007/s00345-021-03607-7
Gilling PJ, Cass CB, Cresswell MD, et al. Holmium laser resection vs transurethral resection of the prostate: a randomized trial. J Urol. 1999;162(5):1640-1644.
Larson TR, Blute ML, Bruskewitz RC, et al. Transurethral microwave thermotherapy for benign prostatic hyperplasia: results of a randomized, controlled, multicenter trial. J Urol. 1998;159(2):475-482.
McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm System study: Minimally invasive thermal therapy for treatment of benign prostatic hyperplasia. Urology. 2018;111:1-9.
Dixon CM, Cedano ER, Pacik D, et al. Water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: international multicenter experience. Urology. 2020;134:112-119.
Darson MF, Alexander EE, Schiffman ZJ, et al. Histological changes after water vapor thermal therapy of the prostate: a multicenter pilot study. J Endourol. 2017;31(7):653-659.
Dixon CM, Rijo Cedano E, Pacik D, et al. Transurethral water vapor thermal therapy for BPH: 2-year results of an international multicenter study. J Endourol. 2020;34(6):548-555.
McVary KT, Gilling P, Roehrborn CG. Preservation of sexual function 5 years after water vapor thermal therapy for BPH. J Urol. 2021;205(3):780-789.
Mynderse LA, Hanson D, Robb RA. Histologic impact of convective water vapor thermal therapy on benign prostatic hyperplasia. Urology. 2015;86(3):538-543.
Rijo Cedano E, McVary KT, Gange SN, et al. Rezūm water vapor therapy for LUTS due to BPH: 2-year outcomes. Prostate Cancer Prostatic Dis. 2019;22(3):411-419.
Gilling PJ, Barber N, Bidair M, et al. Water vapor thermal therapy: Durable 4-year results of the randomized controlled Rezūm II trial. J Urol. 2019;202(4):725-733.
Roehrborn CG, McVary KT, Gange SN, et al. Convective radiofrequency water vapor thermal therapy for BPH: 5-year outcomes. J Urol. 2021;205(4):1084-1093.
Roehrborn CG, McVary KT, Gange SN, et al. Minimally invasive prostate convective water vapor energy ablation: the Rezūm system. Prostate Cancer Prostatic Dis. 2015;18(4):379-385.
McVary KT, Gilling P, Roehrborn CG, et al. Five-year outcomes of water vapor thermal therapy for BPH: results from the randomized controlled Rezūm II trial. Urology. 2021;147:203-210.
Foster HE, Barry MJ, Dahm P, et al. AUA guideline on the management of benign prostatic hyperplasia (BPH). J Urol. 2018;200(3):612-619.
Welliver RC, Mehta A. The cost-effectiveness of minimally invasive surgical therapies for BPH: an evolving landscape. Curr Urol Rep. 2020;21(2):8.
UroSilesia. Terapia parą wodną Rezūm – innowacyjna metoda leczenia przerostu prostaty. https://urosilesia.pl. Dostęp 2025-04-10.
Published
September 11, 2025
Copyright (c) 2025 Mateusz Faryniarz, Jakub Warecki, Magdalena Trólka
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
